newsfilter
← Latest News
GlobeNewswire·

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

  • Candel Therapeutics announced that CEO Paul Peter Tak will present at TD Cowen's 46th Annual Health Care Conference on March 3, 2026, from 11:50 AM to 12:20 PM ET in Boston, MA.
  • A webcast of the presentation will be available via the Investors section of www.candeltx.com, with a replay archived for 90 days.
  • The company focuses on developing off-the-shelf multimodal biological immunotherapies using two clinical-stage platforms based on genetically modified adenovirus & herpes simplex virus (HSV) constructs.
  • Aglatimagene besadenovec (CAN-2409), the lead adenovirus candidate, completed successful phase 2a trials in non-small cell lung cancer (NSCLC) & pancreatic ductal adenocarcinoma (PDAC), while a pivotal phase 3 trial for localized prostate cancer is ongoing under an FDA Special Protocol Assessment.
  • Aglatimagene received FDA Fast Track Designation & Regenerative Medicine Advanced Therapy Designation for newly diagnosed localized prostate cancer, Fast Track Designation for NSCLC, & both Fast Track & Orphan Drug Designations for PDAC.
  • Linoserpaturev (CAN-3110), the lead HSV candidate, is in an ongoing phase 1b trial for recurrent high-grade glioma evaluating repeat injections, with initial results published in Nature & Science Translational Medicine.
  • Linoserpaturev has received FDA Fast Track Designation & Orphan Drug Designation.
  • Candel's enLIGHTEN™ Discovery Platform utilizes an iterative HSV-based approach leveraging human biology & advanced analytics to develop new viral immunotherapies for solid tumors.
  • The press release includes forward-looking statements regarding development timelines, therapeutic benefits, & regulatory outcomes, which are subject to risks & uncertainties outlined in the company's SEC filings.